ClinicalTrials.gg

Leukemia, Lymphocytic, Chronic, B-Cell clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,038 studies for Leukemia, Lymphocytic, Chronic, B-Cell across more than 10 countries. 236 are recruiting or about to start. 1,011 of them are mainly about Leukemia, Lymphocytic, Chronic, B-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

ClinicalTrials.gov finds 2,258 studies for Leukemia, Lymphocytic, Chronic, B-Cell. How that becomes 2,036 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Leukemia, Lymphocytic, Chronic, B-Cell, and those it files under no condition that list Leukemia, Lymphocytic, Chronic, B-Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 2,258Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −21List Leukemia, Lymphocytic, Chronic, B-Cell as a condition, but the registry did not file them under itMost often written as “CLL (Chronic Lymphocytic Leukemia)” (8), “Chronic Lymphocytic Lymphoma” (2), and “B-Chronic Lymphocytic Leukemia” (1). The registry filed them under other conditions only, most often Leukemia, B-Cell (14) and Precursor Cell Lymphoblastic Leukemia-Lymphoma (6).
  3. −212Match it another way25 name it in the title, 5 in a keyword, and 182 by a synonym or other text the search reads.
  4. 2,025Counted here and found by its search7 of them list Leukemia, Lymphocytic, Chronic, B-Cell in their own words; the registry filed them under no condition.
  5. +11
    Counted here, but its search does not find them
  6. 2,036The count on this page

Status

Completed
1,106
Terminated
327
Recruiting
187
Active, not recruiting
149
Status unknown
112
Withdrawn
98

Phase

Phase 2
931
Phase 1
797
Phase 3
178
Phase 4
16
Early Phase 1
16

Where

United States
1,501
France
169
Italy
166
Germany
144
United Kingdom
139
Spain
130

Who develops what

Add Leukemia, Lymphocytic, Chronic, B-Cell to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 35 programs from 18 companies, 23 with this as their studies’ main aim; 13 with a live phase 3 study; 9 primary completions in the next 12 months. Compare Johnson & Johnson, BeOne Medicines and AstraZeneca here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
RituximabRecent, repeated
Evidence
  • NCT07753369 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Rituximab injection” · registered Aug 2026
  • NCT07520006 · Nurix Therapeutics, Inc. · Phase 2 · live · background · “rituximab” · registered Apr 2026
  • NCT07139873 · Dizal Pharmaceuticals · Phase 3 · live · comparator · “Rituximab” · registered Aug 2025
  • NCT06970743 · BeOne Medicines · Phase 3 · live · background · “Rituximab” · registered May 2025
  • NCT06846671 · BeOne Medicines · Phase 3 · live · comparator · “Rituximab” · registered Feb 2025
Hoffmann-La Roche45% of its industry studiesUS: Hoffmann-La Roche (FDA 1997) + 3 othersEU: Hoffmann-La Roche (EMA 1998) + 6 others79 studies
bendamustineRecent, repeated
Evidence
  • NCT07753369 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Bendamustine Injection” · registered Aug 2026
  • NCT07139873 · Dizal Pharmaceuticals · Phase 3 · live · comparator · “Bendamustine” · registered Aug 2025
  • NCT06970743 · BeOne Medicines · Phase 3 · live · background · “Bendamustine” · registered May 2025
  • NCT06846671 · BeOne Medicines · Phase 3 · live · comparator · “Bendamustine” · registered Feb 2025
  • NCT06205290 · Bristol-Myers Squibb · Phase 3 · comparator · “Bendamustine” · registered Dec 2023
Teva Pharmaceutical Industries, Ltd.25% of its industry studiesUS: off-patent, 3 generics marketed56 studies
venetoclaxRecent, repeated
Evidence
  • NCT07520006 · Nurix Therapeutics, Inc. · Phase 2 · live · background · “venetoclax” · registered Apr 2026
  • NCT07277231 · BeOne Medicines · Phase 3 · live · comparator · “Venetoclax” · registered Dec 2025
  • NCT07154264 · Dizal Pharmaceuticals · Phase 2 · live · background · “Venetoclax” · registered Aug 2025
  • NCT06943872 · BeOne Medicines · Phase 3 · live · comparator · “Venetoclax” · registered Apr 2025
  • NCT06846671 · BeOne Medicines · Phase 3 · live · comparator · “Venetoclax” · registered Feb 2025
AbbVie64% of its industry studiesUS: AbbVie (FDA 2016)EU: AbbVie (EMA 2016)47 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT06564038 · AstraZeneca · Phase 2 · live · background · “Cyclophosphamide” · registered Aug 2024
  • NCT06205290 · Bristol-Myers Squibb · Phase 3 · background · “Cyclophosphamide” · registered Dec 2023
  • NCT05624554 · Merck & Co., Inc · Phase 3 · live · comparator · “Cyclophosphamide” · registered Nov 2022
  • NCT04623541 · Genmab · Phase 2 · live · background · “rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone” · registered Oct 2020
  • NCT04416984 · Allogene Therapeutics · Phase 2 · live · background · “Cyclophosphamide” · registered May 2020
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed33 studies
idelalisibRecent, repeated
Evidence
  • NCT07139873 · Dizal Pharmaceuticals · Phase 3 · live · comparator · “Idelalisib” · registered Aug 2025
  • NCT06846671 · BeOne Medicines · Phase 3 · live · comparator · “Idelalisib” · registered Feb 2025
  • NCT06205290 · Bristol-Myers Squibb · Phase 3 · comparator · “Idelalisib” · registered Dec 2023
  • NCT04666038 · Eli Lilly and Company · Phase 3 · live · comparator · “Idelalisib” · registered Dec 2020
  • NCT02970318 · AstraZeneca · Phase 3 · live · comparator · “Idelalisib” · registered Nov 2016
Gilead Sciences93% of its industry studiesUS: Gilead Sciences (FDA 2014)EU: Gilead Sciences (EMA 2014)33 studies
ibrutinibRecent, repeated
Evidence
  • NCT06136559 · Merck & Co., Inc · Phase 3 · live · comparator · “Ibrutinib” · registered Nov 2023
  • NCT05254743 · Eli Lilly and Company · Phase 3 · live · comparator · “Ibrutinib” · registered Feb 2022
  • NCT04494503 · Ascentage Pharma Group International · Phase 2 · live · background · “Ibrutinib” · registered Jul 2020
  • NCT04016805 · TG Therapeutics, Inc. · Phase 2 · background · “Ibrutinib” · registered Jul 2019
  • NCT03734016 · BeOne Medicines · Phase 3 · comparator · “Ibrutinib” · registered Nov 2018
Johnson & Johnson46% of its industry studiesUS: AbbVie (FDA 2013)EU: Johnson & Johnson (EMA 2014)22 studies
obinutuzumabRecent, repeated
Evidence
  • NCT07520006 · Nurix Therapeutics, Inc. · Phase 2 · live · background · “obinutuzumab” · registered Apr 2026
  • NCT06970743 · BeOne Medicines · Phase 3 · live · background · “Obinutuzumab” · registered May 2025
  • NCT06073821 · BeOne Medicines · Phase 3 · live · comparator · “Obinutuzumab” · registered Oct 2023
  • NCT03492125 · MingSight Pharmaceuticals, Inc · Phase 2 · background · “obinutuzumab” · registered Mar 2018
  • NCT03462719 · Johnson & Johnson · Phase 3 · live · comparator · “Obinutuzumab” · registered Mar 2018
Hoffmann-La Roche76% of its industry studiesUS: Hoffmann-La Roche (FDA 2013)EU: Hoffmann-La Roche (EMA 2014)23 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06205290 · Bristol-Myers Squibb · Phase 3 · background · “Fludarabine” · registered Dec 2023
  • NCT05624554 · Merck & Co., Inc · Phase 3 · live · comparator · “Fludarabine” · registered Nov 2022
  • NCT04416984 · Allogene Therapeutics · Phase 2 · live · background · “Fludarabine” · registered May 2020
  • NCT04285567 · Hoffmann-La Roche · Phase 3 · comparator · “Fludarabine” · registered Feb 2020
  • NCT02013817 · Hoffmann-La Roche · Phase 2 · background · “fludarabine” · registered Dec 2013
Beijing Biotech18% of its industry studies22 studies
acalabrutinibRecent, repeated
Evidence
  • NCT07277231 · BeOne Medicines · Phase 3 · live · comparator · “Acalabrutinib” · registered Dec 2025
  • NCT06136559 · Merck & Co., Inc · Phase 3 · live · comparator · “Acalabrutinib” · registered Nov 2023
  • NCT04502394 · Ipsen · Phase 2 · background · “acalabrutinib” · registered Jul 2020
  • NCT04016805 · TG Therapeutics, Inc. · Phase 2 · background · “Acalabrutinib Oral Capsule” · registered Jul 2019
  • NCT03492125 · MingSight Pharmaceuticals, Inc · Phase 2 · background · “acalabrutinib” · registered Mar 2018
AstraZeneca95% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2020)22 studies
pirtobrutinibRecent, repeated
Evidence
  • NCT07342478 · Lupeng Pharmaceutical Ltd. · Phase 3 · live · comparator · “Pirtobrutinib” · registered Jan 2026
  • NCT06973187 · BeOne Medicines · Phase 3 · live · comparator · “Pirtobrutinib” · registered May 2025
Eli Lilly and Company93% of its industry studiesUS: Eli Lilly and Company (FDA 2023)EU: Eli Lilly and Company (EMA 2023)22 studies

18 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ibrutinibApproved: US 2013 · EU 2014☆ Track2 live phase-3 studies: NCT01804686, NCT03462719Johnson & Johnson
acalabrutinibApproved: US 2017 · EU 2020☆ Track5 live phase-3 studies: NCT05057494, NCT02970318, NCT03836261AstraZeneca
pirtobrutinibApproved: US 2023 · EU 2023☆ Track4 live phase-3 studies: NCT05023980, NCT05254743, NCT04666038Eli Lilly and Company
tacabrutideg☆ Track3 live phase-3 studies: NCT06846671, NCT06973187, NCT06970743BeOne Medicines
Immunoglobulins, IntravenousApproved: EU 2006☆ Track1 live phase-3 study: NCT07582432Grifols

The 5 in phase 3 with the nearest primary completion, of 35 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (9)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.sonrotoclax · BeOne Medicines · Phase 2 main aimadded to zanubrutinibNCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia — primary endpoint: Complete Response (CR)/ Complete Response with Incomplete Bone Marrow Recovery (CRi) Rate · 94 enrolled
  • 31 Dec 2026 est.ibrutinib · Johnson & Johnson · Phase 3 main aimNCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) — primary endpoint: Number of participants affected by an adverse event · 539 enrolled
  • Mar 2027 est.tacabrutideg · BeOne Medicines · Phase 2 named, not the main aimNCT05006716 A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies — primary endpoint: Phase 1: Number of Participants with Adverse Events (AEs) · 689 enrolled

6 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Leukemia, Lymphocytic, Chronic, B-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 56 open · Antimetabolites 6 open · Alkylating agents 5 open · Immune checkpoint inhibitors 2 open · mTOR inhibitors 1 open

Coming up

110studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger. 18 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 12 (6%) take healthy volunteers.

Recruiting studies that take each age, of 187
AgeWomenMen
1012 (6%)12 (6%)
18180 (96%)180 (96%)
30182 (97%)182 (97%)
40184 (98%)184 (98%)
50184 (98%)184 (98%)
65185 (99%)185 (99%)
75184 (98%)184 (98%)
85166 (89%)166 (89%)

Across all 2,038 studies, recruiting or not: 18% stop at 75 or younger and 7% at 65; 18% take children; <1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Lymphocytic, Chronic, B-Cell studies take

Of 248 phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 73 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 156 mo39–86 · 180 studies56 mo38–73 · 84 studies56 mo39–91 · 96 studies
Phase 1/278 mo51–103 · 90 studies80 mo51–104 · 50 studies76 mo53–103 · 40 studies
Phase 273 mo41–114 · 248 studies55 mo26–87 · 41 studies75 mo42–119 · 207 studies
Phase 359 mo43–76 · 83 studies53 mo41–73 · 57 studies—
Interventional, no phase42 mo27–134 · 40 studies—42 mo27–134 · 38 studies
Observational60 mo32–176 · 104 studies54 mo35–66 · 34 studies72 mo30–… · 70 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Stopped2

Studies

Recruiting first, then most recently updated. Showing 50 of 2,038. Browse all 2,038 → or search them.